Citations

Clear

959 citation(s) found for "Service, F J".

Seasonal variability is not observed in the rates of high anti‐A and anti‐B titers in plasma, apheresis platelet, and whole blood units tested by different methods
Harm, Sarah K., Yazer, Mark H. , Jacob, Eapen K., Mair, David , Raval, Jay S. , Shaz, Beth H. , Ziman, Alyssa , Collaborative, on behalf of the Biomedical Excellence for Safer Transfusion (BEST), Dunbar, Nancy M , Shaz, Beth H , Ziman, Alyssa , Raval, Jay S , Bub, Carolina Bonet , Cohn, Claudia S. , Kutner, José Mauro , Dunbar, Nancy M. , Collaborative, on behalf of the Biomedical Excellence for Safer Transfusion (BEST)

Mayo Clinic

Transfusion | December 12, 2018 | Volume: 59 | Issue: 2 | Pages: 762-767

10.1111/trf.15083 | PMID 30548267 Get It

BACKGROUNDABO‐incompatible platelet transfusions are common, and transfusions with ABO‐incompatible plasma are increasing with the use of group A plasma and group O whole blood (WB) in emergencies. Many centers screen blood products for anti‐A and/or anti‐B titers to help prevent hemolysis from ABO‐incompatible transfusions, yet titer methods and definition of high titers are not standardized.STUDY DESIGN AND METHODSThis international multicenter study collected data on anti‐A and anti‐B titer practices for plasma, apheresis platelet (AP), and WB units from January 2015 through December 2017 to determine the prevalence of high‐titer units using local definitions.RESULTSA total of 87,701 plasma, AP and WB units were screened for high‐titer anti‐A and/or anti‐B. High‐titer detection rates for group A plasma ranged 0%–13.6%; group A AP 2.7%–9.3%; group O AP 2.3%–65.7%; and group O WB 6.4%–20.7%. At the one center that collected group B AP, the high‐titer rate was 10.9%. High‐titer rates varied from month to month, as well as between years for a given month. There was no clear pattern of when high‐titer units were donated.CONCLUSIONThe prevalence of high‐titer plasma, AP, and WB units varies by titer method and local definition of high titer. Even at the lowest titer threshold of 50, a significant proportion of units had a high‐titer antibody, although the clinical relevance of this finding needs further investigation.
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study
Castillo, Jorge J. , Paludo, Jonas , Varettoni, Marzia , Buske, Christian , Eyre, Toby A. , Chávez, Julio C. , Shain, Kenneth H. , Issa, Samar , Palomba, M. Lia , Pasvolsky, Oren , Simpson, David , Talaulikar, Dipti , Tedeschi, Alessandra , Ansell, Stephen M. , Nayak, Lakshmi , Paludo, Jonas , Buske, Christian , Eyre, Toby A , Chavez, Julio C , Palomba, M Lia , Talaulikar, Dipti , Tam, Constantine S , Tedeschi, Alessandra , Ansell, Stephen M , Treon, Steven , Castillo, Jorge J , Itchaki, Gilad , Tam, Constantine S. , Treon, Steven P. , Varettoni, Marzia , Pasvolsky, Oren

Mayo Clinic

Blood | December 6, 2018 | Volume: 133 | Issue: 4 | Pages: 299-305

10.1182/blood-2018-10-879593 | PMID 30523119 Get It

Abstract The treatment of patients with Bing-Neel syndrome (BNS) is not standardized. We included patients with Waldenström macroglobulinemia (WM) and a radiologic and/or cytologic diagnosis of BNS treated with ibrutinib monotherapy. Response assessment was based on criteria for BNS from the 8th International Workshop for WM. Survival from BNS diagnosis (BNS survival), survival from ibrutinib initiation to last follow-up or death (ibrutinib survival), and time from ibrutinib initiation to ibrutinib discontinuation for toxicity, progression, or death (event-free survival [EFS]) were estimated. Twenty-eight patients were included in our study. The median age at BNS diagnosis was 65 years. Ibrutinib was the first line of treatment for BNS in 39% of patients. Ibrutinib was administered orally at a dose of 560 and 420 mg once daily in 46% and 54% of patients, respectively; symptomatic and radiologic improvements were seen in 85% and 60% of patients within 3 months of therapy. At best response, 85% of patients had improvement or resolution of BNS symptoms, 83% had improvement or resolution of radiologic abnormalities, and 47% had cleared the disease in the cerebrospinal fluid. The 2-year EFS rate with ibrutinib was 80% (95% confidence interval [CI], 58%-91%), the 2-year ibrutinib survival rate was 81% (95% CI, 49%-94%), and the 5-year BNS survival rate was 86% (95% CI, 63%-95%). Ibrutinib therapy is effective in patients with BNS and should be considered as a treatment option in these patients.
Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS ® ) Society Recommendations: 2018
Gustafsson, Ulf , Scott, Michael J. , Hübner, Martin , Demartines, Nicolas , Rockall, Timothy , Young‐Fadok, Tonia M., Soop, Mattias , Boer, Hans D. de , Chang, George J. , Keßler, Hermann, Whang, Edward E. , Fawcett, William , Carli, F. , Lobo, Dileep N. , Rollins, Katie E. , Balfour, Angie , Ljungqvist, Olle , Demartines, N , Lobo, D N , Hübner, Martin , Nygren, Jonas , Francis, Nader Kamal , Hill, Andrew Graham , Urman, Richard D , Fichera, A., Grass, Fabian , Baldini, G., Riedel, Bernhard

Mayo Clinic

World Journal of Surgery | November 13, 2018 | Volume: 43 | Issue: 3 | Pages: 659-695

10.1007/s00268-018-4844-y | PMID 30426190 Get It

Abstract Background This is the fourth updated Enhanced Recovery After Surgery (ERAS ® ) Society guideline presenting a consensus for optimal perioperative care in colorectal surgery and providing graded recommendations for each ERAS item within the ERAS ® protocol. Methods A wide database search on English literature publications was performed. Studies on each item within the protocol were selected with particular attention paid to meta‐analyses, randomised controlled trials and large prospective cohorts and examined, reviewed and graded according to Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system. Results All recommendations on ERAS ® protocol items are based on best available evidence; good‐quality trials; meta‐analyses of good‐quality trials; or large cohort studies. The level of evidence for the use of each item is presented accordingly. Conclusions The evidence base and recommendation for items within the multimodal perioperative care pathway are presented by the ERAS ® Society in this comprehensive consensus review.
Functional regression-based monitoring of quality of service in hospital emergency departments
Das, Devashish , Storlie, Curtis B. , Sır, Mustafa Y. , Pasupathy, Kalyan S.

Mayo Clinic

IISE Transactions | October 16, 2018 | Volume: 51 | Issue: 9 | Pages: 1012-1024

10.1080/24725854.2018.1536303 Get It

Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in Candida and Aspergillus Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion Met
Espinel‐Ingroff, Ana , Turnidge, John , Alastruey‐Izquierdo, Ana , Castro, C. , Chen, Yee‐Chun , Chen, Yan , Chryssanthou, Erja , Dannaoui, Éric , García‐Effrón, Guillermo , Govender, Nelesh P. , Guinea, Jesús , Kidd, Sarah , Lass‐Flörl, Cornelia , Linares-Sicilia, María José, López-Soria, Leire , Magobo, Rindidzani E. , Peláez, Teresa, Quindós, Guillermo , Rodriguez-Iglesia, M. A., Ruiz, Maite, Sánchez, F , Sanguinetti, Maurizio , Shields, Ryan K. , Szweda, Piotr , Wengenack, Nancy L. , Bramati, Simone, Cavanna, C. , DeLuca, C., Grancini, Anna, Negri, C. E., Passera, Marco, Pemán, Javier , Prigitano, Anna , Sala, E., Tejada, M., Alastruey-Izquierdo, A , Dannaoui, E , Govender, N P , Guinea, J , Quindós, G , Sánchez-Reus, F , Sanguinetti, M , Szweda, P , Tortorano, A , Peman, J , Kidd, Sarah E , Botterel, Françoise , Cantón, Rafael , González, Gloria María , Lackner, Michaela , Pipaón, Maite Ruíz-Pérez de , Gelmi, Maria Luisa , Lombardi, Giuseppe , Meletiadis, Joseph

Mayo Clinic

Antimicrobial Agents and Chemotherapy | October 11, 2018 | Volume: 63 | Issue: 1 | Pages: No page available

10.1128/aac.01651-18 | PMID 30323038 Get It

Although the Sensititre Yeast-One (SYO) and Etest methods are widely utilized, interpretive criteria are not available for triazole susceptibility testing of Candida or Aspergillus species. We collected fluconazole, itraconazole, posaconazole, and voriconazole SYO and Etest MICs from 39 laboratories representing all continents for (method/agent-dependent) 11,171 Candida albicans , 215 C. dubliniensis , 4,418 C. glabrata species complex, 157 C. guilliermondii ( Meyerozyma guilliermondii ), 676 C. krusei ( Pichia kudriavzevii ), 298 C. lusitaniae ( Clavispora lusitaniae ), 911 C. parapsilosis sensu stricto , 3,691 C. parapsilosis species complex, 36 C. metapsilosis , 110 C. orthopsilosis , 1,854 C. tropicalis , 244 Saccharomyces cerevisiae , 1,409 Aspergillus fumigatus , 389 A. flavus , 130 A. nidulans , 233 A. niger , and 302 A. terreus complex isolates.
Systematic review with meta‐analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome
Ford, Alexander C. , Harris, Lucinda A. , Lacy, Brian E. , Quigley, Eamonn M.M. , Ford, Alexander C , Quigley, Eamonn M M , Moayyedi, Paul

Mayo Clinic

Alimentary Pharmacology & Therapeutics | October 8, 2018 | Volume: 48 | Issue: 10 | Pages: 1044-1060

10.1111/apt.15001 | PMID 30294792 Get It

Summary Background Irritable bowel syndrome ( IBS ) is a chronic functional bowel disorder. Disturbances in the gastrointestinal microbiome may be involved in its aetiology. Aim To perform a systematic review and meta‐analysis to examine the efficacy of prebiotics, probiotics, synbiotics and antibiotics in IBS . Methods MEDLINE , EMBASE , and the Cochrane Controlled Trials Register were searched (up to July 2017). Randomised controlled trials ( RCT s) recruiting adults with IBS , comparing prebiotics, probiotics, synbiotics or antibiotics with placebo or no therapy were eligible. Dichotomous symptom data were pooled to obtain a relative risk ( RR ) of remaining symptomatic after therapy, with a 95% confidence interval ( CI ). Continuous data were pooled using a standardised mean difference with a 95% CI . Results The search identified 4017 citations. Data for prebiotics and synbiotics were sparse. Fifty‐three RCT s of probiotics, involving 5545 patients, were eligible. Particular combinations of probiotics, or specific species and strains, appeared to have beneficial effects on global IBS symptoms and abdominal pain, but it was not possible to draw definitive conclusions about their efficacy. There were five trials of similar design that used rifaximin in non‐constipated IBS patients, which was more effective than placebo ( RR of symptoms persisting = 0.84; 95% CI 0.79‐0.90). Adverse events were no more common with probiotics or antibiotics. Conclusions Which particular combination, species or strains of probiotics are effective for IBS remains, for the most part, unclear. Rifaximin has modest efficacy in improving symptoms in non‐constipated IBS .
Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline
Speiser, Phyllis , Arlt, Wiebke , Auchus, Richard J. , Baskin, Laurence S. , Conway, Gerard S. , Merke, Deborah P. , Meyer‐Bahlburg, Heino F. L. , Miller, Walter L. , Murad, M. Hassan , White, Perrin C. , Murad, M Hassan , Arlt, Wiebke , Merke, Deborah P , Oberfield, Sharon E.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 28, 2018 | Volume: 103 | Issue: 11 | Pages: 4043-4088

10.1210/jc.2018-01865 | PMID 30272171 Get It

Arthroscopic Treatment of Massive Posterosuperior Rotator Cuff Tears
Wagner, Eric R. , Welp, Kathryn M., Elhassan, Bassem T. , Higgins, Laurence D. , Warner, Jon J.P. , Warner, Jon J P , Wagner, Eric R , Woodmass, Jarret Murray , Chang, Michelle J.

Mayo Clinic

JBJS Reviews | September 28, 2018 | Volume: 6 | Issue: 9 | Pages: e3-e3

10.2106/jbjs.rvw.17.00199 | PMID 30204644 Get It

* Massive rotator cuff tears that are treated nonoperatively demonstrate increases in tear size, fatty infiltration, muscular atrophy, and arthritis. * The pooled retear rate following complete repair of massive rotator cuff tears is 79%. * Absorbable and nonabsorbable graft augmentation following rotator cuff repair can reduce the retear rate and improve functional outcomes. * Irreparable tears can be predicted preoperatively by evaluating the degree of fatty infiltration, muscular atrophy, and tendon length. * Latissimus dorsi transfer, lower trapezius transfer, and superior capsular reconstruction provide improvements in terms of pain, range of motion, and function in patients with irreparable tears.
Providing oncologic care with access to clinical trials to an underserved and minority population: The Mayo Clinic/Indian Health Service experience.
Northfelt, Donald W. , Chamie, Chara, Omar, Farhia, Fitch, Tom R., Okamoto, Janet , Mathews, Timothy

Mayo Clinic

Journal of Clinical Oncology | September 25, 2018 | Volume: 36 | Issue: 30_suppl | Pages: 79-79

10.1200/jco.2018.36.30_suppl.79 Get It

79 Background: Novel mechanisms are needed to provide high quality oncologic clinical care and clinical trial access to underserved and minority populations (UMP). UMP are underrepresented in cancer clinical trials, thus limiting the generalizability of the research. As a National Cancer Institute-Comprehensive Cancer Center, Mayo Clinic has the responsibility to ensure that its cancer care reaches a diverse patient population. Mayo Clinic in Arizona developed a clinical oncology practice in collaboration with the US Indian Health Service at Phoenix Indian Medical Center (PIMC), in part to address these needs. The relationship between Mayo and PIMC is invaluable and serves a crucial need in the community. The Mayo consultants serve as staff physicians in the “Oncology Center of Excellence” at PIMC and see 100 – 200 tribal members annually with new diagnoses of cancer or blood disorders. Being onsite at PIMC allows Mayo consultants to integrate seamlessly into the wider PIMC practice. Methods: Descriptive demographic data from the MCA-PIMC clinical practice were obtained from the PIMC practice database 2008 - 2017. Enrollment of MCA-PIMC patients into MCA cancer clinical trials were prospectively enumerated. Results: Between the time period of 2008-2017, 356 breast cancer patients and 259 colorectal cancer patients were seen by Mayo Clinic oncologists and the PIMC nurse practitioner. During the period of 2016-2017, there were 13 clinical trial referrals from PIMC with 8 of those patients being enrolled in Mayo cancer clinical trials. Conclusions: High quality oncologic clinical care can be provided via unique collaborations between academic oncology program and UMP-focused care provider. This mechanism allows access to cancer clinical trial opportunities for UMP. Prior to the established partnership, there were no Native American patients referred to clinical trials from PIMC, showing the critical pathway that has been forged. Importantly, this is the only known program of its kind in the country. By imbedding the cancer provider in the community, we are able to build trust with the underserved community and create a pathway to a quality care and clinical research.